Drug Trial Radar · NCT06214143
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Jan 11, 2024
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Shanghai Pharmaceuticals Holding Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical study evaluated the efficacy and safety of T3011 in combination with PD-1/PD-L1 inhibitors in subjects with advanced solid tumors
Conditions
- Advanced Solid Tumors
Interventions
T3011 high doseBiological
T3011 high dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W
T3011 middle doseBiological
T3011 middle dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W
T3011 low doseBiological
T3011 low dose: T3011 will be given intratumorally,Q2W; PD-1/PD-L1 inhibitor:Administered by intravenous infusion,3 mg/kg,Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse EventsTime frame: Approximately 2years
- Objective response rate(ORR)Time frame: Approximately 2years
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Anyang Cancer Hospital
Anyang, China · Recruiting
The First Affiliated Hospital of Bengbu Medical University
Bengbu, China · Recruiting
Hunan cancer hospital
Changsha, China · Recruiting
Sichuan Cancer Hospital
Chengdu, China · Recruiting
Dongguan People's Hospital
Dongwan, China · Recruiting
Fujian Cancer Hospital
Fuzhou, China · Recruiting
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
The First Affiliated Hospital of Guangdong Pharmaceutical University
Guangzhou, China · Recruiting
Harbin Medical University Cancer Hospital
Ha’erbin, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Recruiting
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China · Recruiting
Shandong cancer hospital
Jinan, China · Recruiting
Jiangxi cancer hospital
Nanchang, China · Recruiting
Guangxi Medical University Affiliated Cancer Hospital
Nanning, China · Recruiting
Shanghai East Hospital
Shanghai, China · Recruiting
Shanghai Ninth People's Hospital
Shanghai, China · Recruiting
Liaoning Cancer Hospital
Shenyang, China · Recruiting
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, China · Recruiting
Shanxi Cancer Hospital
Taiyuan, China · Recruiting
Tianjin cancer hospital
Tianjin, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Henan cancer hospital
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.